Seminars in Nephrology
Volume 27, Issue 2 , Pages 130-143, March 2007

AGE, RAGE, and ROS in Diabetic Nephropathy

  • Adeline L.Y. Tan, BBiomedSc

      Affiliations

    • A.L.Y.T. is supported by a Kidney Health Australia Medical Research Funding Award.
  • ,
  • Josephine M. Forbes, PhD

      Affiliations

    • J.M.F. is a Juvenile Diabetes Research Foundation career development awardee
  • ,
  • Mark E. Cooper, PhD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Mark E. Cooper, Albert Einstein Centre for Diabetes Complications, Baker Heart Research Institute, PO Box 6492, St Kilda Rd, Central Melbourne, Victoria 8008, Australia.

Albert Einstein Centre for Diabetes Complications, Baker Heart Research Institute, Melbourne, Victoria, Australia.

Summary 

Diabetic nephropathy is a major cause of morbidity and mortality in diabetic patients. Two key mechanisms implicated in the development of diabetic nephropathy include advanced glycation and oxidative stress. Advanced glycation is the irreversible attachment of reducing sugars onto amino groups of proteins to form advanced glycation end products (AGEs). AGE modification of proteins may lead to alterations in normal function by inducing cross-linking of extracellular matrices. Intracellular formation of AGEs also can cause generalized cellular dysfunction. Furthermore, AGEs can mediate their effects via specific receptors, such as the receptor for AGE (RAGE), activating diverse signal transduction cascades and downstream pathways, including generation of reactive oxygen species (ROS). Oxidative stress occurs as a result of the imbalance between ROS production and antioxidant defenses. Sources of ROS include the mitochondria, auto-oxidation of glucose, and enzymatic pathways including nicotinamide adenine dinucleotide phosphate reduced (NAD[P]H) oxidase. Beyond the current treatments to treat diabetic complications such as the optimization of blood pressure and glycemic control, it is predicted that new therapies designed to target AGEs, including AGE formation inhibitors and cross-link breakers, as well as targeting ROS using novel highly specific antioxidants, will become part of the treatment regimen for diabetic renal disease.

Keywords: Diabetes mellitus, diabetic nephropathy/complications, advanced glycation end-products, receptors, oxidative stress

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported in part by the Juvenile Diabetes Research Foundation, National Health and Medical Research Council of Australia, Diabetes Australia, and the National Institutes of Health.

PII: S0270-9295(07)00007-1

doi:10.1016/j.semnephrol.2007.01.006

Seminars in Nephrology
Volume 27, Issue 2 , Pages 130-143, March 2007